Cardiovascular effects of dapagliflozin in patients on chronic dialysis: the DARE-ESKD-2 randomized clinical trial
收藏DataCite Commons2026-02-26 更新2026-05-07 收录
下载链接：
https://redu.unicamp.br/citation?persistentId=doi:10.25824/redu/OXTXSM
下载链接
链接失效反馈官方服务：
资源简介：
This dataset encompass Dare-Eskd-2 trial information, a prospective, randomized, open-label, blinded endpoint trial performed at 3 dialysis clinics between January 2023 and September 2024, that enrolled 80 consecutive adults on chronic dialysis to either once daily dapagliflozin 10mg or standard care for 24 weeks. Efficacy endpoints comprised the change from baseline to 24 weeks in NT-proBNP, KCCQ-CCS, 6-minute walk test distance.
提供机构：
Repositório de Dados de Pesquisa da Unicamp
创建时间：
2025-09-03
